A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 07 May 2012
At a glance
- Drugs PF 4958242 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 May 2012 Actual patient number 30 added as reported by ClinicalTrials.gov.
- 07 May 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
- 07 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.